The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

ORLADEYO net revenue reached $148.3 million, driven by new patient prescriptions tracking slightly ahead of 2025 averages despite new injectable competition.

Management attributes ORLADEYO's resilience to its unique oral profile, noting that new injectable launches are primarily competing with existing injectable market leaders rather than oral prophylaxis.

The pivotal ALPHA-ORBIT trial for navenibart is exceeding enrollment expectations, which management views as a testament to patient appetite for 3-month and 6-month dosing regimens.

Strategic portfolio refinement led to the discontinuation of avoralstat in DME as the company continues to evaluate internal programs to focus on a disciplined R&D strategy.

The integration of Astria Therapeutics is running ahead of schedule, demonstrating the company's capability to execute and absorb transformational business development deals.

A manufacturing issue with ORLADEYO pediatric pellets has delayed initial fulfillment, though management clarified this is a batch specification issue at a separate facility and not a safety or regulatory concern.

Full-year 2026 ORLADEYO revenue guidance is maintained at $625 million to $645 million, assuming the pediatric manufacturing delay is resolved relatively quickly.

Navenibart regulatory filing in the U.S. remains on track for late 2027, supported by the completion of Phase 3 enrollment expected by the end of June 2026.

Proof-of-concept data for BCX17725 in Netherton syndrome is anticipated by year-end 2026, with plans to potentially initiate a pivotal program in 2027.

R&D expenses are projected to increase throughout 2026 to support Phase 3 completion and BLA-enabling CMC activities for navenibart.

Management reaffirmed a long-term peak sales target of $1 billion for ORLADEYO, citing consistent prescriber growth and high patient retention after the first year.

Recorded a $698 million in-process R&D charge in Q1 related to the Astria acquisition, which was treated as an asset acquisition for accounting purposes.

Secured a $70 million upfront payment through a licensing agreement with Neopharmed Gentili for navenibart in Europe, strengthening the pro forma liquidity to $331 million.

The company closed a $400 million senior credit facility to fund the cash portion of the Astria acquisition, contributing to a lower overall cost of capital.

Non-GAAP operating profit increased 25% year-on-year to $54 million, reflecting the company's ability to scale revenue while maintaining a steady-state sales and marketing structure.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management stated that recent injectable launches are primarily impacting the market leader TAKHZYRO rather than ORLADEYO.

ORLADEYO demand remains at record levels, and the company has not found it necessary to change its sales force size or physician targeting strategy.

The issue is identified as a batch specification problem at a partner manufacturing plant, distinct from the capsule production facility.

Management expects to identify the root cause and provide a specific readiness update later in the current quarter.

Management expects the Phase 3 data to mirror Phase 2 results, where patients achieved a mean attack rate of 0.16 per month (functionally attack-free).

The trial assumes comparable efficacy between the 3-month and 6-month arms because the 6-month regimen utilizes twice the dose.

BioCryst estimates the U.S. market for Netherton syndrome at over 3,000 patients.

Management believes the introduction of a targeted therapy will act as a catalyst for increased patient identification and correct diagnosis in this rare disease space.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.